利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

82 条记录 (耗时 0.039 秒)

    Therapeutic compounds
    12.
    发明授权
    Therapeutic compounds 有权
    治疗化合物

    公开(公告)号：US08044092B2

    公开(公告)日：2011-10-25

    申请号：US12860518

    申请日：2010-08-20

    申请人： Yariv Donde ,  Robert M. Burk ,  David W. Old

    发明人： Yariv Donde ,  Robert M. Burk ,  David W. Old

    IPC分类号： A61K31/4015 ,  C07D409/06

    CPC分类号： C07C405/00 ,  C07C59/56 ,  C07C59/90 ,  C07C2601/04 ,  C07C2601/14

    摘要： A compound having a substituted five or six-membered carbocycle or heterocycle directly bonded to a substituted aryl or heteroaryl ring, wherein said compound has an EC50 value of 20 nM or less at the prostaglandin EP2 receptor according to the cAMP assay.Methods, compositions, and medicaments related thereto are also disclosed.

    摘要翻译： 具有与取代的芳基或杂芳基环直接结合的取代的五元或六元碳环或杂环的化合物，其中所述化合物根据cAMP测定在前列腺素EP2受体的EC 50值为20nM以下。 还公开了与之相关的方法，组合物和药物。

    Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
    14.
    发明授权
    Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents 有权
    环戊烷庚烷（ENE）OIC酸，2-杂芳基烯基衍生物作为治疗剂

    公开(公告)号：US07906552B2

    公开(公告)日：2011-03-15

    申请号：US10916243

    申请日：2004-08-10

    申请人： Yariv Donde ,  Robert M. Burk ,  Michael E. Garst

    发明人： Yariv Donde ,  Robert M. Burk ,  Michael E. Garst

    IPC分类号： A61K31/38 ,  A61K31/5575 ,  C07D333/24 ,  C07C405/00

    CPC分类号： C07C405/00 ,  C07D333/28

    摘要： A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.

    摘要翻译： 公开了具有本文详细描述的基团的化合物或其药学上可接受的盐或其前药。 本文还公开了包含其衍生物或其衍生物的化合物或其结构或衍生物的化合物的药学上可接受的盐，四唑或前药，所述衍生物在此详细描述。 本文还公开了治疗疾病或病症的方法，包括青光眼和眼内压升高。 还公开了与其相关的药物制备的组合物和方法。

    Prostaglandin EP4 antagonist
    16.
    发明授权
    Prostaglandin EP4 antagonist 有权
    前列腺素EP4拮抗剂

    公开(公告)号：US07273883B2

    公开(公告)日：2007-09-25

    申请号：US10952418

    申请日：2004-09-27

    申请人： David Woodward ,  Achim H. Krauss ,  Yariv Donde ,  Robert M. Burk

    发明人： David Woodward ,  Achim H. Krauss ,  Yariv Donde ,  Robert M. Burk

    IPC分类号： A61K31/422

    CPC分类号： C07D493/08

    摘要： Disclosed herein are methods and compositions related to compound 1 or a pharmaceutically acceptable salt, or a prodrug thereof (all of which are referred to hereafter, collectively or individually, as “compound 1”), which is an antagonist of a prostaglandin EP4 receptor, or is a prostaglandin EP4 antagonist. Also disclosed is a method comprising administering a prostaglandin EP4 antagonist to a mammal suffering from, or at risk of developing, a disease or condition selected from the group consisting of cancer, immunological disorders, neurodegenerative disorders, ocular diseases, hepatic diseases, renal diseases, septicemia, fibromyalgia, dermatological disorders, and antipyrexia.

    摘要翻译： 本文公开了与化合物1或其药学上可接受的盐或其前药（以下统称为或单独地称为“化合物1”）相关的方法和组合物，其为前列腺素的拮抗剂EP 4 受体，或是前列腺素EP 4拮抗剂。 还公开了一种方法，其包括向患有或处于发展中的疾病或病症的哺乳动物施用前列腺素EP 4拮抗剂，所述疾病或病症选自癌症，免疫学障碍，神经变性疾病，眼睛 疾病，肝脏疾病，肾脏疾病，败血症，纤维肌痛，皮肤病和止血症。